ABOUT 11th_OIF
> AGENDA
> REGISTRATION
> ATTENDEES
> INVESTORS
> PRESENTERS
​​> SPONSORS
​​> SUPPORTERS
> NETWORKING
> VENUE
> ACCOMMODATION

> ABOUT LAST EVENT

20-minute presenters

7 Hills Pharma Inc.

7 Hills Pharma is a Houston-based, clinical-stage drug development company advancing first-in-class, oral small molecules leveraging the novel mechanism of selective allosteric integrin activation (SAIA), pioneered by 7HP's co-founders, to safely enhance the effectiveness of immunotherapies against solid tumors, blood cancers, and genetic disorders with no added toxicities. 
 
Launched in 2016, 7 Hills Pharma has received over $29 million in state and federal grants to accelerate our programs, including over $20 million since 2022, following an intensive due diligence process for each award.  Our proven management team has deep experience from discovery through approval, enabling 7 Hills to efficiently advance novel small molecule integrin activators from discovery through Phase II clinical proof-of-concept, our preferred exit point. 
 
We are advancing two developmental programs, each with a dedicated first-in-class molecule, toward significant value inflection milestones offering liquidity potential within 2-3 years.

www.7hillspharma.com

Cullinan Therapeutics, Inc.
[​NASDAQ: CGEM]

Cullinan Therapeutics, Inc. is a biopharmaceutical company developing potential first- or best-in-class, high-impact therapies for autoimmune diseases and cancer. Cullinan pursues promising therapeutic targets while leveraging core expertise in T cell engagers, which are established in oncology and are now advancing into autoimmune diseases. With a clinical-stage pipeline built on a rigorous scientific approach and purposeful innovation, Cullinan is advancing its mission to deliver new standards of care for patients.

www.cullinantherapeutics.com

10-minute presenters

Accession Therapeutics Ltd.

Creating the ideal immunotherapy for solid tumors which provides potent tumour-selective delivery and tumour-selective killing ability through IV delivery. Lead program entering the clinic in 2025.​

www.accessiontherapeutics.com

Ascensus Therapeutics, Inc.

A synthetic biology platform company developing a new technology for directly modulating cytokine signaling pathways in health and disease states that represents a paradigm shift from traditional approaches to harnessing the power of the immune system. Our lead program will improve treatment strategies for solid tumors and autoimmune diseases.

www.ascensusrx.com

Biomunex Pharmaceuticals

BIOMUNEX Pharmaceuticals is a clinical-stage biopharmaceutical company based in Paris, led by an international team, focused on the discovery and development of disruptive immuno-therapeutics in oncology, thanks to its proprietary next-generation bi- and multi-specific antibody, the BiXAb® platform.

Biomunex is developing a disruptive biological approach, the MAIT-engagers, that redirect MAIT cells to kill cancer cells, which may become a true game changer in the field of cancer immunotherapy.

www.biomunex.com

Biond Biologics Ltd.

Biond Biologics – Advancing First-in-Class Immunotherapies

Biond Biologics is a private, clinical-stage biotechnology company developing a pipeline of first-in-class immunotherapies for cancer and immune-related diseases. Our programs target novel pathways across both innate and adaptive immunity, supported by deep translational science and biomarker-driven clinical development.

www.biondbio.com

NEOK Bio, Inc.

NEOK Bio is a therapeutics company developing novel bispecific antibody drug conjugates (ADCs) to improve outcomes for cancer patients

www.neokbio.com

OxSonics

OxSonics is a game changing MedTech company, spun out from the University of Oxford, a Focused Ultrasound Center of Excellence. The company has developed a novel, breakthrough ultrasound-mediated drug delivery platform to significantly improve delivery of anti-cancer drugs into the target tumor site. Located in Oxford, the team is made of 7 people whose 50% are PhD.

SonoTran® is a platform comprising a proprietary ultrasound engine and Sonosensitive Particles which are co-administered and systemically infused alongside anti-cancer drugs.

OxSonics has recached a major inflection point with the completed In first‑in‑human mCRC trial , SonoTran® improved response rates (86% vs 67%), with complete responses in 4/7 patients  without any device-related safety issues reported.

www.oxsonics.com